The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Development Of Antibodies To Il-13 Receptor And Their Preclinical Testing In A Sheep Model For Human Allergic Asthma
Funder
National Health and Medical Research Council
Funding Amount
$435,375.00
Summary
The increasing prevalence and severity of asthma worldwide highlights the need for novel approaches to treat this disease. This proposal will generate antibodies that can be used to specifically block the action of a key molecule known to regulate many of the hallmark features of asthmatic disease. Preclinical evaluation of these antibodies in an established sheep model of human asthma will allow their assessment as a specific therapy for asthma.
Targeting MiRNA To Inhibit Leukocyte Differentiation: A Novel Anti-inflammatory Approach For The Treatment Of Asthma
Funder
National Health and Medical Research Council
Funding Amount
$601,386.00
Summary
In asthma, the symptoms are caused by an allergic reaction in the lung and the production of inflammatory cells whose maturation is guided by tiny molecules called “microRNAs”. The critical microRNAs will be identified and strategies to block their function developed and tested for their ability to inhibit allergic inflammation to evaluate this approach as a new treatment for asthma.
Aberrant Signalling Through Gp130 In The Pathogenesis Of Fibrotic Lung Diseases
Funder
National Health and Medical Research Council
Funding Amount
$456,500.00
Summary
Pulmonary fibrosis is a chronic diffuse interstitial lung disease of unknown cause, characterised pathologically by inflammation and fibrosis of the lung tissue. The prognosis is poor with a 50% mortality at five years after diagnosis and considerable morbidity during those years. Previous investigations have documented the role for inflammation in the development of pulmonary fibrosis and current therapeutic strategies are aimed at suppressing the inflammation. Data generated over the past deca ....Pulmonary fibrosis is a chronic diffuse interstitial lung disease of unknown cause, characterised pathologically by inflammation and fibrosis of the lung tissue. The prognosis is poor with a 50% mortality at five years after diagnosis and considerable morbidity during those years. Previous investigations have documented the role for inflammation in the development of pulmonary fibrosis and current therapeutic strategies are aimed at suppressing the inflammation. Data generated over the past decade also have established the concept that the molecular processes underlying the fibrogenesis component may represent a new opportunity for therapeutic intervention. Attempts to treat fibrosis have for the most part consisted of anti- inflammatory drugs, almost exclusively steroids. The effectiveness of steroids is variable and can be associated with significant side effects. This project will examine the effects of a family of molecules called cytokines that signal through gp130 as critical determinants of disease susceptibility and progression. gp 130 is a shared component in the receptor complexes for IL-6 family cytokines (IL-6, IL-11, LIF, OSM) which are important regulators of both the phenotype and proliferation of fibroblasts in health and in response to injury. Our data raises the possibility of developing pharmacological manipulators of gp130 signalling pathways that would suppress fibrosis but leave normal cellular defense mechanisms necessary for host defense in the lung intact.Read moreRead less
Switching Tristetraprolin On To Turn Off Inflammation In COPD
Funder
National Health and Medical Research Council
Funding Amount
$525,390.00
Summary
Inflammation drives the pathogenesis of chronic obstructive pulmonary disease (COPD). We have developed a novel anti-inflammatory strategy to treat this currently untreatable disease. Our innovation is to use activators of protein phosphatase 2A to switch the molecule tristetraprolin (TTP) on and repress inflammation in COPD. Switching TTP on to turn off inflammation in COPD has proven potential to prevent irreversible damage and halt the progression of COPD.
Asthma is a significant burden to the health care system and to individual sufferers. Currently we can treat asthma with corticosteroids to reduce inflammation in the lung but the side effects of these medications, particularly in children, make them less than ideal treatments. In order to design a more specific treatment for asthma, which would only target the inflammatory cells which are involved in the lung, we need to understand how these cells behave and what initiates the cascade of events ....Asthma is a significant burden to the health care system and to individual sufferers. Currently we can treat asthma with corticosteroids to reduce inflammation in the lung but the side effects of these medications, particularly in children, make them less than ideal treatments. In order to design a more specific treatment for asthma, which would only target the inflammatory cells which are involved in the lung, we need to understand how these cells behave and what initiates the cascade of events in the lung. This project is designed to investigate how chemical mediators, cytokines, are produced by various cells in the lung and how they induce lung cells to make structural changes to the lung tissue and increase the inflammation. The source and specific types of cytokines released are being investigated to provide important information regarding the disease process of asthma. From this new knowledge, design of specific new treatments, with fewer unwanted side-effects, should be possible.Read moreRead less
Cytokines Regulating Airway Inflammation, Remodelling And Hyper-reactivity In Chronic Asthma
Funder
National Health and Medical Research Council
Funding Amount
$329,500.00
Summary
This project examines a new approach to treatment of asthma, based on immunisation against the body's own chemical signals. The investigators will also be continuing studies on how twitchy airways develop in asthma, the mechanisms by which scarring of the airway walls progresses, and the signals that trigger inflammation of the airways. These studies will use a much-improved mouse model of the disease. In this experimental model, which was developed by the investigators, sensitised mice are chro ....This project examines a new approach to treatment of asthma, based on immunisation against the body's own chemical signals. The investigators will also be continuing studies on how twitchy airways develop in asthma, the mechanisms by which scarring of the airway walls progresses, and the signals that trigger inflammation of the airways. These studies will use a much-improved mouse model of the disease. In this experimental model, which was developed by the investigators, sensitised mice are chronically exposed to low concentrations of aerosolised egg white protein. The proposed studies will involve comparisons with animals that are immunised against certain inflammation-related molecules, as well as with mice that are genetically deficient in their ability to produce such molecules. The results of these studies may help in the development of methods for long-term suppression of the changes that develop in the airways of asthmatics.Read moreRead less
I am a pulmonary physician-gene therapist persuing new therapies for pulmonary vascular disease, lung cancer and mesothelioma, COPD and lung transplant rejection
Altered Gp130-mediated Signalling In The Regulation Of Pulmonary Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$373,956.00
Summary
Pulmonary fibrosis is a chronic diffuse interstitial lung disease often of unknown cause, characterised pathologically by inflammation and fibrosis of the lung tissue. The prognosis is poor with a 50% mortality at five years after diagnosis and considerable morbidity during those years. Previous investigations have documented the role for inflammation in the development of pulmonary fibrosis and current therapeutic strategies are aimed at suppressing the inflammation using anti- inflammatory dru ....Pulmonary fibrosis is a chronic diffuse interstitial lung disease often of unknown cause, characterised pathologically by inflammation and fibrosis of the lung tissue. The prognosis is poor with a 50% mortality at five years after diagnosis and considerable morbidity during those years. Previous investigations have documented the role for inflammation in the development of pulmonary fibrosis and current therapeutic strategies are aimed at suppressing the inflammation using anti- inflammatory drugs, almost exclusively steroids. The effectiveness of steroids is variable although generally poor and can be associated with significant side effects suggesting that other approaches need to be considered. Data generated over the past decade also have established the concept that the molecular processes underlying the development of fibrosis may represent a new opportunity for therapeutic intervention. This project will build on previous studies examining the effects of a family of molecules called cytokines that signal through gp130 as critical determinants of disease susceptibility and progression. gp 130 is a shared component in the receptor complexes for IL-6 family cytokines and can signal down two major pathways. We have shown that the development of lung fibrosis depends on which specific signalling pathway is used. This study will determine how fibrosis is controlled by these pathways. Our data raises the possibility of developing pharmacological manipulators of gp130 signalling pathways that would suppress fibrosis but leave normal cellular defense mechanisms necessary for host defense in the lung intact.Read moreRead less
THE ROLE OFPROTEASES AND PROTEASE ACTIVATED RECEPTORS IN RESPIRATORY EPITHELIAL CELL FUNCTION IN ASTHMA
Funder
National Health and Medical Research Council
Funding Amount
$457,500.00
Summary
The epithelium lines the airways and is, therefore, constantly exposed to a variety of exogenous antigens, infectious agents and noxious stimuli. This tissue responds to such stimuli by secreting substances that help counteract the insult while simultaneously initiating healing and repair. In this proposal, we will investigate the role of a group of receptors present on the surface of the epithelium which monitor the area surrounding the epithelium for the presence of enzymes which digest host t ....The epithelium lines the airways and is, therefore, constantly exposed to a variety of exogenous antigens, infectious agents and noxious stimuli. This tissue responds to such stimuli by secreting substances that help counteract the insult while simultaneously initiating healing and repair. In this proposal, we will investigate the role of a group of receptors present on the surface of the epithelium which monitor the area surrounding the epithelium for the presence of enzymes which digest host tissue or pathogens. These receptors, known as PAR, sense their suroundings by binding the protease, a process which then triggers the cell to respond in an appropriate way by releasing cytokines and mediators. There are 4 PAR, each with different properties, and are present on many cells of the body. However, little information about their role on epithelium exists. Although we have shown them to be upregulated in the epithelium in the socio-economically important disease, asthma, their function in this disease remains elusive. We will, therefore, initiate studies to define their role in inflammation, healing and repair as this information may lead to a better understanding of their role in disease which may then translate into better treatment.Read moreRead less
Understanding Corticosteroid-sensitive And -insensitive Pathways In Airway Remodelling
Funder
National Health and Medical Research Council
Funding Amount
$299,270.00
Summary
Asthma and chronic obstructive pulmonary disease (COPD) are chronic disorders of the airways affecting millions of people worldwide. Airways become remodelled, or thickened, resulting in airway obstruction and decline in lung function. Approximately 400 asthmatics and 6000 COPD sufferers die in Australia each year. Worryingly, COPD is currently the fourth highest cause of death in Australia and this number is predicted to increase in the future. Unfortunately, the drugs currently available for c ....Asthma and chronic obstructive pulmonary disease (COPD) are chronic disorders of the airways affecting millions of people worldwide. Airways become remodelled, or thickened, resulting in airway obstruction and decline in lung function. Approximately 400 asthmatics and 6000 COPD sufferers die in Australia each year. Worryingly, COPD is currently the fourth highest cause of death in Australia and this number is predicted to increase in the future. Unfortunately, the drugs currently available for combating these diseases have limited success. We need to understand how to control airway remodelling to be able to improve treatments for asthma and COPD. But first we require a greater understanding of the molecular mechanism-s underlying the development of airway remodelling. With this proposal we will increase our knowledge of the mechanistic basis of asthma and COPD and may elucidate novel therapeutic targets for future pharmacological intervention.Read moreRead less